Editorial stack guide · Joint recovery
Joint recovery: BPC-157, TB-500, collagen
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Joint recovery stack
BPC-157, TB-500 and ingestible collagen are three compounds discussed in the context of joint and tendon recovery. They sit in different regulatory categories: BPC-157 and TB-500 are research peptides without UK marketing authorisation, while hydrolysed collagen is a food supplement. Evidence weight differs sharply across the three. PeptideClear publishes encyclopedia commentary only. We do not recommend specific stacks for specific people. A combination of peptides should be discussed with a UK-registered prescriber.
Compounds discussed for joint and tendon recovery
Three distinct compound classes appear in joint-recovery conversations. The evidence weight, mechanism, and UK regulatory status differ sharply. Treat each as a separate research lane, not as components of a single protocol.
BPC-157
Evidence: Animal onlyBPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a fragment of a protein found in human gastric juice. Discovered and characterised in the 1990s by the Sikiric group at the University of Zagreb. The preclinical literature in rodent models describes tissue-protective and pro-angiogenic effects across tendon, gut, vascular and bone tissue. No published phase II or phase III human clinical trials.
Encyclopedia entry for BPC-157 ·TB-500
Evidence: Animal onlyTB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-residue peptide involved in cell migration and actin sequestration. The animal-model literature reports effects on wound repair, cell migration and tissue regeneration. The compound is on the World Anti-Doping Agency (WADA) prohibited list. There are no published human RCTs for joint or tendon endpoints.
Encyclopedia entry for TB-500 ·Hydrolysed collagen peptides
Evidence: Human RCTHydrolysed collagen (collagen peptides) is a mixture of short peptide chains produced by enzymatic breakdown of collagen protein. Sources include bovine hide, marine fish skin, and porcine collagen. Multiple human randomised controlled trials report effects on joint comfort, skin elasticity and bone density markers. Sits in the food supplement category in the UK, regulated by the Food Standards Agency.
Collagen hub ·What the literature shows
The Sikiric research group at the University of Zagreb has published the bulk of the BPC-157 literature, with most rodent papers reporting accelerated tendon healing, gut barrier protection, and angiogenesis. Independent replication outside the originating group remains limited. The animal-model picture is reasonably consistent within that lineage. The translation gap to humans has not been closed by published RCT data.
TB-500 literature centres on Thymosin Beta-4 fragment activity. Researchers report effects on actin binding via the Ku-80 pathway and downstream cell migration in wound-repair models. Published work spans cardiology, ophthalmology, and dermatology preclinical contexts. Human trial work in non-tendon endpoints exists for the parent compound. Tendon-specific human RCTs are not published.
Collagen peptide research sits in a different category. Trial work from the Proksch group, the Zdzieblik trials at the German Sport University Cologne, and the McAlindon analyses of undenatured Type II collagen describe measurable effects on joint comfort scores and structural markers. Daily doses studied typically range from 2.5 to 15 grams over 12 to 24 weeks. The evidence base is human, randomised, and replicated across independent groups.
What we do not know
- · Whether BPC-157 effects observed in rodent models transfer to human tendon or joint endpoints at any dose, in any population.
- · Whether TB-500 produces measurable improvement in human joint recovery at any dose or duration.
- · Whether combining BPC-157 and TB-500 produces additive, synergistic or null effect versus either compound alone in any human endpoint.
- · Whether adding collagen peptides to either research peptide changes the trajectory of joint or tendon recovery in any controlled trial.
- · Long-term safety of BPC-157 or TB-500 in humans at any dose, including immunogenicity, off-target receptor activity, and effects on undiagnosed neoplastic tissue.
- · Whether observed effects in the animal literature reflect peptide activity or are artefacts of the rodent stress and injury models used.
UK regulatory framing
BPC-157
Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Sold legally as a research chemical when marketed without health claims. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
TB-500
Same UK position as BPC-157 (no MoDA listing, no PSA listing, no MHRA marketing authorisation). Additionally on the WADA prohibited list (S2: peptide hormones, growth factors, related substances and mimetics). Tested athletes in any WADA-aligned sport should treat this as a hard exclusion.
Hydrolysed collagen peptides
Sold as a food supplement under UK food law. Regulated by the Food Standards Agency. Authorised health claims under the GB Nutrition and Health Claims Register are limited. Most product marketing must avoid medicinal claim language and rely on the food supplement category framing.
How a UK practitioner would discuss this
A UK musculoskeletal practitioner approaching the joint-recovery conversation will typically anchor on the clinical evidence base first. That means physiotherapy-led rehabilitation, progressive loading, and where appropriate orthopaedic referral. Hydrolysed collagen peptides sit comfortably in this conversation as a food supplement with human trial data, often used alongside a structured rehab plan rather than as a substitute for it.
Research peptides occupy a different conversation. A UK-registered prescriber discussing BPC-157 or TB-500 would frame them as research compounds without UK clinical-trial backing, without marketing authorisation, and without an established safety profile for the relevant population. The conversation typically centres on the gap between animal evidence and human evidence, the absence of a pharmacovigilance reporting route for off-label research compounds, and the practical reality that no UK clinic stocks or administers them in clinical practice.
PeptideClear does not provide that practitioner conversation. We document the compounds, the evidence, and the regulatory framing. The decision to act on any of it sits between you and a UK-registered prescriber familiar with your clinical history.
Where to learn more
- · Encyclopedia entry: BPC-157
- · Encyclopedia entry: TB-500
- · Collagen hub: ingestible collagen overview
- · Collagen types: Type I, II, III collagen explained
- · Retailer comparison: Best UK BPC-157 retailers
- · Retailer comparison: Best UK TB-500 retailers
- · Retailer comparison: Best UK collagen brands
- · Glossary: peptide terminology reference
Frequently asked questions
Is the BPC-157 plus TB-500 plus collagen combination evidence-based?
Are BPC-157 and TB-500 legal to buy in the UK?
Does combining them work better than one alone?
Who should I speak to before considering a combination?
Is collagen really a peptide?
PeptideClear publishes encyclopedia commentary only. We do not recommend specific stacks for specific people. A combination of peptides should be discussed with a UK-registered prescriber. Every research peptide on this page is sold under research-use-only framing. Hydrolysed collagen is a food supplement regulated under UK food law.
Read our full methodology and how we are funded.
Ready to buy
Shop UK peptides, collagen and GLP-1 routes
Compare UK retailers, clinics and pharmacies across every PeptideClear category.